Skip to main content

Table 1 Patient characteristics (as treated)

From: Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A

  TARGIT-A   EBRT+boost  
  IORT (n = 25) EBRT (n = 46) IORT-EBRT (n = 16)   IORT-boost (n=90) EBRT-boost (n=53)  
  No. % No. % No. % P* No. % No. % P**
Age, years             
 Mean 65.5 65.2 61.8 0.276 60.1 49.9 <0.001
 SD 8.5 8.2 6.0   11.1 9.2  
Married/partnered 14 58 22 48 13 81 0.066 58 64 39 76 0.191
Employed 4 16 9 20 0 0 0.185 27 31 31 60 <0.001
Months since BCS             
 Mean 32.7 30.6 35.6 0.641 34.2 47.5 <0.001
 SD 19.1 17.2 19.6   13.7 7.4  
Tumor size             
 0-1 cm 8 32 14 30 3 19 0.376 13 14 6 11 0.414
 1-2 cm 16 64 25 34 9 56   49 54 23 43  
 > 2 cm 1 4 7 15 4 25   28 31 24 45  
Nodal involvement             
 N0 23 92 36 78 14 88 0.622 66 73 34 65a 0.253
 N1 2 9 9 20 2 12   20 22 11 21  
 > N1 0 0 1 2 0 0   4 4 7 13  
ALND 4 16 14 30 4 25 0.409 55 61 41 79a <0.001
Chemotherapy 4 17 5 11 2 12 0.908 18 20 36 68 <0.001
Endocrine therapy 23 96 40 93 13 81 0.322 70 78 36 86 0.349
Radiotherapy of supra- and infraclavicular nodes 0 0 2 4 0 0 0.693 7 8 10 19 0.049
Medical comorbidities ≥2b 14 56 37 80 11 69 0.091 49 54 9 17 <0.001
  1. Abbreviations: TARGIT-A, TARG eted I ntra-operative radioT herapy versus whole breast radiotherapy for breast cancer, IORT, intraoperative radiotherapy, EBRT, external beam whole breast radiotherapy, ALND, axillary lymph node dissection.
  2. * IORT versus EBRT versus IORT-EBRT.
  3. ** IORT-EBRT versus IORT-boost versus EBRT-boost.
  4. a One patient without axillary assessment.
  5. b Coexisting medical conditions were assessed by medical record review and by patient self-report. A medical comorbidity was defined as having two or more physical illnesses or injuries that needed long-term treatment.